Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents

被引:0
|
作者
Gonzalez-Lama, Yago [1 ]
Isabel Vera, Maria [1 ]
Calvo, Marta [1 ]
Abreu, Lluis [1 ]
机构
[1] Hosp Univ Puerta Hierro, Serv Gastroenterol & Hepatol, Unidad Enfermedad Inflamatoria Intestinal, Madrid, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2010年 / 33卷 / 06期
关键词
Crohn's disease; Ulcerative colitis; Azathioprine; Infliximab; Adalimumab; FISTULIZING CROHNS-DISEASE; REFRACTORY ULCERATIVE-COLITIS; SCHEDULED MAINTENANCE TREATMENT; SINGLE-CENTER EXPERIENCE; LONG-TERM EFFICACY; INFLIXIMAB THERAPY; MAGNETIC-RESONANCE; FECAL CALPROTECTIN; PREDICTIVE FACTORS; RANDOMIZED-TRIAL;
D O I
10.1016/j.gastrohep.2009.11.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Immunosuppressive or biological treatment in patients with inflammatory bowel disease can modify the natural history of their disease, although these treatments are not universally effective and can have severe adverse effects. Attempts have been made to identify predictive factors of response to the various therapeutic options in order to aid the choice of the most appropriate therapeutic alternative in each patient. The possibility of modifying any one of these predictive factors would be of great interest since it would provide the opportunity to alter the course of the disease. Epidemiological, biological, clinical, endoscopic, radiological, genetic and even proteomic markers have been studied, in addition to others related to the disease itself or to specific treatments. The present article briefly discusses the real use of each of these markers and the evidence supporting their utility. (C) 2009 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:449 / 460
页数:12
相关论文
共 50 条
  • [1] Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents
    Roslyn Kemp
    Elliott Dunn
    Michael Schultz
    BioDrugs, 2013, 27 : 585 - 590
  • [2] Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents
    Kemp, Roslyn
    Dunn, Elliott
    Schultz, Michael
    BIODRUGS, 2013, 27 (06) : 585 - 590
  • [3] Must immunomodulators be added to biological treatment in inflammatory bowel disease?
    Gomollon, Fernando
    Gisbert, Javier P.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2010, 33 (01): : 43 - 53
  • [4] Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era
    Campos, Sara
    Portela, Francisco
    Sousa, Paula
    Sofia, Carlos
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 28 (11) : 1313 - 1319
  • [5] Effects of Immunomodulators and Biologic Agents on Sexual Health in Inflammatory Bowel Disease
    Kanar, Ozdemir
    Berry, Andrew C.
    Nakshabendi, Rahman
    Aldridge, Petra
    Myers, Travis
    Eid, Emely
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S1256 - S1257
  • [6] LONGTERM OUTCOME OF PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH IMMUNOMODULATORS
    van Hoeve, Karen
    Hoffman, Ilse
    Ferrante, Marc
    Vermeire, Severine
    GASTROENTEROLOGY, 2019, 156 (06) : S612 - S613
  • [7] Quality of life in patients with inflammatory bowel disease treated with thiopurinic immunomodulators
    Nos, P
    Bastida, G
    Rubin, A
    Beltran, B
    Ponce, J
    GASTROENTEROLOGY, 2005, 128 (04) : A323 - A324
  • [8] Immunogenicity of biological agents in inflammatory bowel disease
    Fefferman, DS
    Farrell, RJ
    INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) : 497 - 503
  • [9] MONITORING THE PSYCHOPATHOLOGICAL PROFILE OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS TREATED WITH BIOLOGICAL AGENTS
    Balzoni, L. M.
    D'Onofrio, A. M.
    Ferrajoli, G. F.
    Di Vincenzo, F.
    Sani, G.
    Gasbarrini, A.
    Scaldaferri, F.
    Camardese, G.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S216 - S216
  • [10] Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators
    Subramanian, V.
    Pollok, R. C. G.
    Kang, J. -Y.
    Kumar, D.
    BRITISH JOURNAL OF SURGERY, 2006, 93 (07) : 793 - 799